Morgan Stanley Q2 Beat Fails to Shift Cyclical Peak Thesis

What happened

Morgan Stanley reported Q2 earnings of $3.46 per share, beating estimates by $0.57 and nearly doubling year-ago earnings, driven by continued strength in investment banking and trading. This marks another quarter of outperformance in a capital-markets cycle that has produced record revenues and returns for the firm. However, our DeepValue analysis maintains that 2025's performance was a cyclical high and that normalized ROTCE is closer to mid-teens, well below the ~20% embedded in the current stock price. The Q2 beat does not alter the base-case fair value of $180, implying limited upside and significant downside risk if IB and trading activity reverts. Consequently, we view the earnings beat as a sell-the-news opportunity for existing holders and recommend avoiding new positions at these levels.

Implication

The Q2 beat may extend the cyclical tailwind, but investors should use any further strength to reduce exposure. The structural thesis of normalized ROTCE mid-teens and WM margin pressure remains intact, making current valuation unattractive. Wait for a pullback to $165 or evidence of sustained 20%+ ROTCE through a quieter quarter before re-entering.

Thesis delta

The Q2 2026 earnings beat, while strong, does not invalidate the core thesis that 2025 was a cyclical peak and that current multiples embed unsustainable profitability. The near-term momentum could delay normalization, but the risk-reward remains skewed to the downside given elevated expectations and limited valuation buffer.